Skip to main content
Luye Pharma Group Limited logo

Luye Pharma Group Limited — Investor Relations & Filings

Ticker · 2186 HKEX Manufacturing
Open in API
Filings indexed 1,503 across all filing types
Latest filing 2025-03-14 Board/Management Inform…
Country HK Hong Kong
Listing HKEX 2186

About Luye Pharma Group Limited

http://www.luye.cn

Luye Pharma Group is an international pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative medications, novel formulations, and biopharmaceutical products. The company's core strategy emphasizes advanced drug delivery systems, including microspheres, liposomes, and transdermal technologies, to enhance therapeutic efficacy and patient compliance. Luye Pharma maintains a strong focus on key therapeutic areas, particularly the Central Nervous System (CNS). Its portfolio includes proprietary products such as Roxinlin® (Toludesvenlafaxine extended-release tablets) and various long-acting injectable antipsychotic formulations, positioning the group as a global pharmaceutical enterprise.

Recent filings

Filing Released Lang Actions
NOTICE OF BOARD MEETING
Board/Management Information Classification · 91% confidence The document is a short announcement titled “NOTICE OF BOARD MEETING” and states that the board will meet to approve annual results and consider dividend. It is a Board/Management information announcement regarding a board meeting scheduling, not a full financial report or proxy materials. Therefore, it falls under the Board/Management Information category (MANG).
2025-03-14 English
CHANGE OF NON-EXECUTIVE DIRECTOR
Board/Management Information Classification · 95% confidence The document is an official announcement by Luye Pharma Group Ltd. regarding the appointment and resignation of non-executive directors. It specifically details a board change (Mr. Huang Liming’s appointment and Dr. Lyu Dong’s resignation), which falls under ‘Board/Management Information’ (MANG).
2025-03-10 English
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Board/Management Information Classification · 90% confidence The document is a formal announcement listing the company’s board of directors, their roles (executive, non-executive, independent), and committee memberships. This corresponds to a Board/Management Information disclosure rather than an annual report or governance policy manual. Therefore, it is classified as MANG (Board/Management Information).
2025-03-10 English
Monthly Return of Equity Issuer on Movements in Securities
Regulatory Filings Classification · 90% confidence The document is an HKEX FF301 Monthly Return for Equity Issuer and Hong Kong Depositary Receipts, covering movements in authorized share capital, issued and treasury shares, share options, and confirmations under Listing Rules. It is not an earnings or annual report, not a dividend notice, and contains no announcement of an upcoming report. Instead, it is a regulatory form filed monthly to the exchange. It does not fit any other specific category (e.g., share issue announcement, M&A, or management changes), so it falls under the general Regulatory Filings category.
2025-03-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2025
Regulatory Filings Classification · 88% confidence The document is a monthly return (FF301) filed to Hong Kong Exchanges & Clearing under Listing Rule Chapter 19B, detailing share capital movements and confirmations. It is a regulatory submission rather than a management discussion, earnings release, or investor presentation. It does not announce a specific capital transaction or dividend, nor does it present full financial results. It is the actual periodic regulatory return itself (length ~9,000 characters), not merely an announcement that a report is available. Therefore, it is best classified under the general “Regulatory Filings” category (RNS).
2025-03-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025
Regulatory Filings Classification · 92% confidence The document is titled “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules” (Form FF301) and is addressed to HKEX. It provides a detailed month-end return of authorized share capital, issued shares, treasury shares, and convertibles under the Exchange’s listing rules. It is a routine regulatory filing under the Exchange Listing Rules rather than a financial report, capital-raising announcement, or other specialised filing. Therefore, it best fits the general Regulatory Filings category (RNS).
2025-02-05 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.